The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Incorporating comparative effectiveness research study endpoints into the treatment for positive-node, endocrine-responsive breast cancer (RxPONDER) study.
S. D. Ramsey
No relevant relationships to disclose
W. E. Barlow
No relevant relationships to disclose
C. Moinpour
No relevant relationships to disclose
A. M. Gonzalez-Angulo
No relevant relationships to disclose
G. N. Hortobagyi
No relevant relationships to disclose
D. L. Veenstra
Consultant or Advisory Role - Genentech; Novartis
L. P. Garrison
No relevant relationships to disclose
S. R. Tunis
No relevant relationships to disclose
L. H. Baker
No relevant relationships to disclose